Neoadjuvant Chemoradiotherapy plus Surgery versus Surgery Alone for Esophageal or Junctional Cancer (CROSS Trial)
Source: View publication →
The CROSS trial demonstrated that neoadjuvant chemoradiotherapy with carboplatin and paclitaxel followed by surgery significantly improves long-term overall survival compared to surgery alone in patients with resectable esophageal or esophagogastric junctional cancer.
Key Findings
Study Design
Study Limitations
Clinical Significance
The CROSS regimen established a new standard of care for locally advanced, resectable esophageal and gastroesophageal junction cancer. Its favorable toxicity profile and consistent long-term survival benefit have made it a cornerstone of multimodal therapy globally.
Historical Context
Prior to the CROSS trial, the management of resectable esophageal cancer was inconsistent, with many centers performing surgery alone due to lack of high-level evidence for neoadjuvant therapy. By providing definitive phase III evidence for the survival benefit and safety of a specific chemoradiotherapy regimen, the trial resolved significant clinical uncertainty and transformed the standard management approach.
Guided Discussion
High-yield insights from every perspective
Based on the biological principles of oncology, why is 'neoadjuvant' chemoradiotherapy potentially more effective for locally advanced esophageal cancer than 'adjuvant' (post-operative) therapy?
Key Response
Neoadjuvant therapy addresses micrometastatic disease earlier in the treatment course and increases the likelihood of an R0 (microscopically negative margin) resection by shrinking the primary tumor. Additionally, the blood supply and oxygenation of the tumor bed are usually intact before surgery, which enhances the efficacy of radiation-induced free radical damage compared to the relatively hypoxic environment of post-surgical scar tissue.
For a patient with a T3N1 esophageal squamous cell carcinoma being treated according to the CROSS protocol, what is the specific chemotherapy regimen used and what is the expected rate of pathological complete response (pCR)?
Key Response
The CROSS regimen consists of weekly carboplatin (AUC 2) and paclitaxel (50 mg/m2) for 5 weeks concurrently with 41.4 Gy of radiation. For squamous cell carcinoma, the CROSS trial demonstrated a remarkably high pCR rate of 49%, which is significantly higher than the approximately 23% pCR rate observed for adenocarcinoma.
Considering the long-term (10-year) follow-up of the CROSS trial, how do the patterns of recurrence differ between the neoadjuvant chemoradiotherapy group and the surgery-alone group, particularly regarding local versus distant control?
Key Response
The CROSS trial showed that neoadjuvant CRT significantly reduces both local and regional recurrence. In the long-term analysis, the primary benefit remained the reduction in local-regional relapse (14% vs 34%). While distant metastases were also reduced, the most profound impact was the achievement of durable local-regional control, which translated into a sustained overall survival benefit across 10 years of monitoring.
Given the results of the ESOPEC trial which compared the CROSS regimen to perioperative FLOT, how should your multidisciplinary team decide between these two standards for a fit patient with distal esophageal adenocarcinoma?
Key Response
The ESOPEC trial recently suggested that perioperative FLOT (5-FU, leucovorin, oxaliplatin, docetaxel) provides superior overall survival compared to the CROSS regimen in patients with adenocarcinoma. Therefore, FLOT is increasingly favored for distal AC in fit patients. However, CROSS remains the preferred option for patients with squamous cell carcinoma, those who are older/frailer and cannot tolerate triplet chemotherapy, or those with tumors located higher in the esophagus where surgical margins are more precarious.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The CROSS trial utilized a radiation dose of 41.4 Gy, which is lower than the traditional 50.4 Gy used in definitive chemoradiation. Critically analyze the statistical and radiobiological implications of using this lower dose on the trial's ability to demonstrate non-inferiority in local control vs. surgical morbidity.
Key Response
The selection of 41.4 Gy was a strategic trade-off intended to maximize the R0 resection rate while minimizing radiation-induced perioperative complications (like anastomotic leaks or pulmonary toxicity). From a methodology standpoint, this dose was sufficient to achieve high pCR rates without the toxicity ceiling seen in trials like INT 0123. The success of this dose-fractionation protocol established a new standard for 'pre-operative' dosing as distinct from 'definitive' dosing.
In evaluating the internal validity of the CROSS trial, how might the high percentage of patients with squamous cell carcinoma (SCC) in the original cohort limit the generalizability of the overall survival hazard ratio to a North American or Western European population where adenocarcinoma is now the dominant histology?
Key Response
As a reviewer, one would flag that the treatment effect was significantly more robust in the SCC subgroup (HR 0.48) than in the adenocarcinoma subgroup (HR 0.73). Because the trial pooled these histologies, the impressive overall hazard ratio of 0.65 is somewhat skewed by the SCC results. Editors would require clear subgroup reporting to ensure that clinicians do not overestimate the benefit for adenocarcinoma patients, who constitute the majority of current Western cases.
Current NCCN guidelines list the CROSS regimen as a Category 1 recommendation for both adenocarcinoma and SCC. Should the guidelines be updated to create a hierarchy between CROSS and perioperative chemotherapy for adenocarcinoma based on recent comparative data, and what is the strength of evidence for this change?
Key Response
Guidelines are shifting toward a 'histology-driven' approach. While CROSS is the undisputed standard for SCC (Level 1 evidence), for adenocarcinoma, the NCCN and ESMO are moving toward prioritizing perioperative chemotherapy (like FLOT) based on the superior survival outcomes in the ESOPEC and FLOT4 trials. The committee must decide if CROSS should be relegated to 'preferred in specific circumstances' for AC, such as when the patient is not a candidate for taxane-based triplets or has borderline resectable local disease.
Clinical Landscape
Noteworthy Related Trials
MAGIC Trial
Tested
Perioperative ECF chemotherapy
Population
Resectable gastric, junctional, or distal esophageal adenocarcinoma
Comparator
Surgery alone
Endpoint
Overall survival
POET Trial
Tested
Preoperative chemoradiotherapy
Population
Patients with adenocarcinoma of the esophagogastric junction
Comparator
Preoperative chemotherapy
Endpoint
3-year survival rate
FLOT4 Trial
Tested
Perioperative FLOT chemotherapy
Population
Resectable gastric or gastroesophageal junction adenocarcinoma
Comparator
Perioperative ECF/ECX chemotherapy
Endpoint
Overall survival
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis